StockNews.AI
BBNX
StockNews.AI
173 days

Beta Bionics to Announce Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

1. BBNX plans to release Q4 and 2024 financial results on March 25. 2. Management will host a conference call for performance review. 3. iLet Bionic Pancreas is the first FDA-cleared insulin delivery device. 4. Beta Bionics aims to improve health for insulin-dependent diabetes patients.

4m saved
Insight
Article

FAQ

Why Bullish?

The upcoming financial results could indicate growth and improved market perception, similar to previous quarterly earnings announcements that often led to positive price movements in tech stocks.

How important is it?

The scheduled announcement and potential positive updates are likely to influence investor confidence and stock price.

Why Short Term?

Immediate focus on Q4 results will drive market sentiment and trading activity in the following month.

Related Companies

MDTABTSNY
February 27, 2025 07:00 ET  | Source: Beta Bionics, Inc. IRVINE, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) -- Beta Bionics, Inc. (Nasdaq: BBNX), a pioneering leader in the development of advanced diabetes management solutions, today announced that it plans to release its fourth quarter and full year 2024 financial results after the financial markets close on Tuesday, March 25, 2025. Management will host a conference call and concurrent webcast on the same day at 4:30 pm Eastern Time (1:30 pm Pacific Time), to review the company’s fourth quarter and full year 2024 performance. The link to the webcast will be available on the Company’s website in the “Investors—Events & Presentations” section at https://investors.betabionics.com, and will be archived there for future replay. To access the live call by phone, please use the following link, which will provide you with dial-in details and a personal pin: https://register-conf.media-server.com/register/BI8be51a4e688845529dd55d442f427c91. About Beta Bionics Beta Bionics, Inc. is a commercial-stage medical device company engaged in the design, development, and commercialization of innovative solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing advanced adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The iLet Bionic Pancreas is the first FDA-cleared insulin delivery device that autonomously determines every insulin dose and offers the potential to substantially improve overall outcomes across broad populations of PWD. To learn more, visit www.betabionics.com. Investor Relations:Blake BeberHead of Investor Relationsir@betabionics.com Media and Public Relations: Karen HynesVice President of Marketingmedia@betabionics.com Source: Beta Bionics, Inc.

Related News